Another study has indicated that TNF-α signals through ITK-Akt-mTOR to drive CD4+ T cell glucose metabolism reprogramming in RA, which suggests that target components of this signaling axis may thus represent a potential therapeutic strategy for modulating T cell glucose metabolism in RA (39). This evidence concerns the gene AKT1 and rheumatoid arthritis.